Camurus AB (publ): history, ownership, mission, how it works & makes money

From a Lund laboratory in 1991 where scientists pioneered lipid-based nanoscale drug delivery, Camurus AB has grown into a publicly traded biotech force (Nasdaq Stockholm: CAMX) that in 2025 opened a 3,700 m² LEED Gold headquarters in Science Village designed for up to 250 employees and launched a new US office in Princeton to sharpen its North American footprint; led by President and CEO Fredrik Tiberg and backed by institutional owners including Första AP-fonden and AMF, the company leverages its proprietary FluidCrystal® platform to develop long-acting medicines (Buvidal® for opioid dependence, royalties from Brixadi® in the US) while generating revenue via product sales, licensing, royalties, milestone payments and strategic collaborations such as the 2025 partnership with Eli Lilly-financially supported by a cash balance of SEK 3.5 billion (Q3 2025) and recent quarterly performance with revenues up 52% to SEK 676 million and profit before tax rising 195% to SEK 307 million (Q2 2025); with a market capitalization near SEK 10 billion, projected 2025 revenues of SEK 2.7-3.0 billion and profit before tax guidance of SEK 0.9-1.2 billion, Camurus is advancing launches (Oczyesa®/CAM2029 in the EU) and clinical programs (CAM2029 expansions, Phase 1 CAM2056 once‑monthly semaglutide depot) while maintaining a science-led, patient-centric and sustainability-focused mission to address dependence, pain, cancer and endocrine diseases.

Camurus AB (0RD1.L): Intro

• Founded in 1991 in Lund, Sweden, by scientists specializing in biophysical, food and pharmaceutical chemistry to commercialize nanoscale lipid phase drug-delivery systems.
• From inception the company prioritized long‑acting medicines for severe and chronic diseases based on its proprietary FluidCrystal® technology.
• January 2025: opened a new headquarters in Science Village, Lund - approximately 3,700 square meters of laboratories and offices designed to accommodate up to 250 employees.
• 2025: expanded its international footprint with a new office in Princeton, New Jersey, to strengthen North American operations.
• 2025: the new Lund headquarters achieved LEED Gold certification, underlining commitments to sustainability and energy efficiency.

• Listed as Camurus AB (0RD1.L) - ownership structure is a mix of institutional investors, specialist life‑science funds, and company insiders and employees.
• Major investor types typically include pension and asset managers, venture and growth investors, and strategic partners tied to commercial collaborations and licensing agreements.

• Develop safer, more effective long‑acting drug formulations that improve patient outcomes in severe and chronic disease areas.
• Use proprietary FluidCrystal® lipid‑based technology to deliver sustained therapeutic exposure, reduce dosing frequency, and enable parenteral administration where oral therapy is inadequate.

• Core technology: FluidCrystal® - lipid‑based liquid crystalline formulations that can encapsulate small molecules, peptides and biologics to create long‑acting depots for subcutaneous or intramuscular injection.
• Product design: tailor release profiles (weeks to months) by altering lipid phase behavior, drug loading and formulation geometry to control diffusion and depot dissolution.
• Development approach: in‑house formulation science, preclinical PK/PD modeling, and clinical development pathways aimed at regulatory approvals and commercial partnerships.

• Technology focus: proprietary FluidCrystal® platform enabling long‑acting injectable medicines measured in weeks to months.
• Facilities: 3,700 m² modern HQ labs/offices in Science Village, Lund (capacity ~250 employees) with LEED Gold certification.
• Geographic footprint: Sweden HQ plus expanded presence in North America (Princeton, NJ) to support U.S./global commercialization and regulatory activities.
• Commercial model: combination of direct commercialization in selected markets and partner/licensing agreements to scale globally.

Camurus AB (0RD1.L): History

• Public listing: Nasdaq Stockholm, ticker CAMX.
• Market capitalization (2025): ~SEK 10 billion.
• Shareholder base: institutional, private and retail investors.

• Ownership structure highlights:
  • Institutional investors (including Första AP-fonden and AMF Försäkring och Fonder) hold significant stakes as of Dec 2025.
  • Remaining shares distributed among private and retail investors, creating a diverse ownership mix.
• Governance and leadership:
  • Board provides strategic guidance drawing on pharma/biotech expertise.
  • Executive management, led by Fredrik Tiberg, manages day-to-day operations and execution of strategic initiatives.

Camurus AB (0RD1.L): Ownership Structure

• Founded: 1991 (Sweden)
• Headquarters: Lund, Sweden (new HQ targeted LEED Gold certification in 2025)
• Core technology: FluidCrystal® long‑acting injectable drug delivery platform
• Therapeutic focus: dependence (opioid use disorder), pain management, oncology, endocrine disorders

• Organizational values:
  • Patient-centric development: design therapies to improve adherence and outcomes for chronic and severe diseases
  • Science-led innovation: heavy R&D investment to advance proprietary formulations
  • Collaboration: licensing and co-development partnerships with global pharma and biotech
  • Sustainability: facility design and operations aligned with environmental certification (LEED Gold HQ in 2025)

• Revenue streams:
  • Product sales-commercialized long‑acting medicines sold in multiple markets (wholesale and direct to health systems)
  • Partnering/license fees-upfront payments, milestones and royalties from co‑development and licensing agreements
  • Contract manufacturing/technical services-provision of formulation know‑how using FluidCrystal® for collaborators
• Business model drivers:
  • Proprietary platform (FluidCrystal®) enables premium positioning of long‑acting injectables, supporting higher margins versus generic injectables
  • Focus on chronic, severe indications increases lifetime patient value and recurring revenue
  • Strategic partnerships accelerate market access and share development risk while delivering milestone and royalty income
• Ownership dynamics:
  • Institutional investors and large biotech/pharma partners hold material stakes that align incentives toward commercial scale‑up and sustained R&D investment
  • Management and founder-related ownership supports long‑term strategy focused on innovation and patient outcomes
  • Public shareholder base provides access to capital markets for financing pipeline expansion and manufacturing capacity

Camurus AB (0RD1.L): Mission and Values

• Prolong therapeutic exposure and reduce dosing frequency
• Improve patient adherence and quality of life
• Enhance pharmacokinetic profiles to reduce peak-trough variability

• Out-licensing of formulation technology for partner-led commercialization
• Co-development arrangements combining Camurus' delivery expertise with partner clinical/regulatory capabilities
• Manufacturing and supply agreements to scale commercial product supply

• Commercial sales of long-acting therapeutics developed in-house
• Upfront, milestone and royalty payments from licensing partners
• Co-development fees and service income tied to formulation expertise

Camurus AB (0RD1.L): How It Works

• Core technology: FluidCrystal® lipid-based formulations that provide controlled release over weeks to months.
• Flagship products: Buvidal® (long-acting buprenorphine for opioid dependence) and marketed ex-U.S. as Brixadi® in the U.S. market through partner agreements.
• Commercial model: Combination of direct product sales, licensing/royalty arrangements, milestone payments and strategic collaborations.

• Product sales: Direct sales of proprietary products such as Buvidal® to healthcare systems and distributors.
• Royalties and licensing fees: Ongoing royalties from partners marketing products in territories (notably material royalties from Brixadi® sales in the U.S.).
• Collaborations and partnerships: Upfront payments, development funding and milestone payments from partners (including the announced partnership with Eli Lilly and Company in 2025).
• Milestone receipts: Conditional payments tied to regulatory approvals, commercial launches or development achievements.

• Buvidal® product sales remain the primary revenue driver in markets where Camurus commercializes directly or via distributors.
• U.S. royalties from Brixadi® substantially contribute to recurring revenue streams; these royalties are a function of partner sales performance in the large U.S. opioid-dependence market.
• Strategic collaborations (e.g., the 2025 agreement with Eli Lilly) provide non-dilutive funding, R&D leverage and milestone potential that can materially boost revenue when targets are met.
• Milestone and licensing income tends to be lumpy but can markedly increase quarterly results, as reflected in Q2 2025 performance.

• Product-margin profile: Proprietary, long-acting formulations command premium pricing versus short-acting alternatives, supporting higher gross margins on product sales.
• Royalty economics: Royalties from partners provide high-margin, low-cost revenue once products are launched by licensees.
• Collaborations and milestone payments: Can materially improve profitability in quarters when milestones are achieved-contributing to the sharp increase in profit before tax in Q2 2025.

• Geographic expansion and deeper market penetration for Buvidal®/Brixadi®.
• New product launches based on FluidCrystal® for additional indications (pain, endocrine disorders, etc.).
• Additional licensing deals and selective partnerships to scale distribution and capture royalties without equivalent commercial overhead.

Camurus AB (0RD1.L): How It Makes Money

• Core commercial products: Buvidal® (extended-release buprenorphine for opioid dependence) - direct product sales in multiple countries drive recurring revenue.
• Royalties and licensing: Brixadi® (depot buprenorphine) produces significant royalty income in the US via partner agreements.
• Product launches and net sales: Oczyesa® (CAM2029) approved in the EU for acromegaly is positioned to add direct sales as it rolls out commercially.
• R&D collaborations and milestone payments: Partnerships leveraging Camurus' lipid-based depot technology generate upfronts, milestones, and cost-sharing income.
• Pipeline value creation: Clinical progress (CAM2029 studies, once-monthly semaglutide CAM2056 Phase 1) increases licensing and future sales potential.

• Market position & outlook: Camurus holds a leading position in opioid dependence treatment via Buvidal®, while Brixadi® royalties underpin US income; strategic expansion and a strengthened HQ/US presence aim to broaden market reach and commercialization capacity.
• Innovation & pipeline: Continued clinical progress (CAM2029 indications, CAM2056) and strategic collaborations are central to revenue growth and long-term value.